A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial

Trial Profile

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 14 Apr 2016 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top